Related Experiment Videos
Gangliosides for acute ischaemic stroke
1Istituto di Clinica Neurologica, Universita di Milano, Ospedale Maggiore, Via F. Sforza 35, 20122 Milano, Italy. pitagora@imiucca.csi.unimi.it
The Cochrane Database of Systematic Reviews
|May 5, 2000
Summary
Exogenous gangliosides did not show significant benefits for acute ischemic stroke patients. While some disability improvements were noted, caution is advised due to rare adverse events like Guillain-Barré syndrome.
Area of Science:
- Neurology
- Pharmacology
Background:
- Gangliosides are compounds with potential neuroprotective properties.
- Their role in central and peripheral nervous system health is under investigation.
Purpose of the Study:
- To evaluate the efficacy and safety of exogenous gangliosides in treating acute ischemic stroke.
- Assessing ganglioside impact on patient outcomes and adverse events.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) comparing gangliosides with placebo or standard care.
- Inclusion criteria: ischemic stroke patients randomized within 15 days of symptom onset with available mortality data.
- Data extraction and quality assessment performed by independent reviewers.
Main Results:
- Eleven trials with 2257 participants using monosialoganglioside GM1 were analyzed.
- No significant difference in mortality was observed between ganglioside and control groups.
- A potential improvement in disability scores (Barthel index) was noted in some trials, but adverse events, including skin reactions and Guillain-Barré syndrome, were reported.
Conclusions:
- Current evidence is insufficient to support the routine use of exogenous gangliosides for acute ischemic stroke.
- The potential risk of rare but serious adverse events, such as Guillain-Barré syndrome, necessitates caution.